NASDAQ:ANIP - ANI Pharmaceuticals Stock Price, Forecast & News

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

ANI Pharmaceuticals Inc (NASDAQ:ANIP) posted its quarterly earnings data on Wednesday, November, 6th. The specialty pharmaceutical company reported $1.23 earnings per share for the quarter, missing the consensus estimate of $1.43 by $0.20. The specialty pharmaceutical company earned $51.30 million during the quarter, compared to analyst estimates of $56.10 million. ANI Pharmaceuticals had a net margin of 7.58% and a return on equity of 28.28%. The company's revenue was up 1.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.29 EPS. View ANI Pharmaceuticals' Earnings History.

ANI Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for ANI Pharmaceuticals.

ANI Pharmaceuticals will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

ANI Pharmaceuticals updated its FY 2019 Pre-Market earnings guidance on Tuesday, December, 3rd. The company provided EPS guidance of 5.06-5.23 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.14. The company issued revenue guidance of $209-212 million, compared to the consensus revenue estimate of $209.67 million.

4 analysts have issued 1 year target prices for ANI Pharmaceuticals' stock. Their forecasts range from $76.00 to $90.00. On average, they expect ANI Pharmaceuticals' stock price to reach $84.25 in the next twelve months. This suggests a possible upside of 37.1% from the stock's current price. View Analyst Price Targets for ANI Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ANI Pharmaceuticals.

News articles about ANIP stock have trended very positive recently, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ANI Pharmaceuticals earned a news sentiment score of 3.1 on InfoTrie's scale. They also gave media stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for ANI Pharmaceuticals.

Some companies that are related to ANI Pharmaceuticals include Apellis Pharmaceuticals (APLS), ChemoCentryx (CCXI), Taro Pharmaceutical Industries (TARO), Uniqure (QURE), Amicus Therapeutics (FOLD), Insmed (INSM), Arena Pharmaceuticals (ARNA), ArQule (ARQL), Biohaven Pharmaceutical (BHVN), Karuna Therapeutics (KRTX), Epizyme (EPZM), Principia Biopharma (PRNB), Aurinia Pharmaceuticals (AUPH), Ra Pharmaceuticals (RARX) and Synthorx (THOR).

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (GILD), Broadcom (AVGO), Teva Pharmaceutical Industries (TEVA), Micron Technology (MU), Alibaba Group (BABA), AbbVie (ABBV), Cisco Systems (CSCO), NXP Semiconductors (NXPI) and Skyworks Solutions (SWKS).

ANI Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include State Street Corp (2.56%), Investment Counselors of Maryland LLC (2.35%), Goldman Sachs Group Inc. (2.31%), Renaissance Technologies LLC (2.20%), Hawk Ridge Capital Management LP (1.56%) and Global Alpha Capital Management Ltd. (1.40%). Company insiders that own ANI Pharmaceuticals stock include Arthur Przybyl, Daniel Raynor, David Nash, James G Marken, Meridian Venture Partners Ii L, Robert W Schrepfer, Thomas Haughey and Tracy Marshbanks. View Institutional Ownership Trends for ANI Pharmaceuticals.

ANIP stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Bank of New York Mellon Corp, Renaissance Technologies LLC, Mackay Shields LLC, SG Americas Securities LLC, LSV Asset Management, Chicago Equity Partners LLC and Perkins Capital Management Inc.. Company insiders that have sold ANI Pharmaceuticals company stock in the last year include Arthur Przybyl, James G Marken, Meridian Venture Partners Ii L and Robert W Schrepfer. View Insider Buying and Selling for ANI Pharmaceuticals.

ANIP stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Hawk Ridge Capital Management LP, California Public Employees Retirement System, Man Group plc, Acadian Asset Management LLC, Global Alpha Capital Management Ltd., First Trust Advisors LP and Russell Investments Group Ltd.. Company insiders that have bought ANI Pharmaceuticals stock in the last two years include David Nash and Thomas Haughey. View Insider Buying and Selling for ANI Pharmaceuticals.

Shares of ANIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ANIP stock can currently be purchased for approximately $61.44.

ANI Pharmaceuticals has a market capitalization of $742.81 million and generates $201.58 million in revenue each year. The specialty pharmaceutical company earns $15.49 million in net income (profit) each year or $4.61 on an earnings per share basis. ANI Pharmaceuticals employs 299 workers across the globe.View Additional Information About ANI Pharmaceuticals.

The official website for ANI Pharmaceuticals is http://www.anipharmaceuticals.com/.

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company can be reached via phone at 218-634-3500 or via email at [email protected]